RxDoctor Payments DataLook up a doctor →

Michael Vavra, MD

Neurology · Lincoln, NENPI 1114182359

Payments from drug & device makers

$6,893in general payments, 2019–2025

Across 359 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$915
  • MDD US Operations, LLC$520
  • Lundbeck LLC$419
  • Biogen$359
  • UCB, Inc.$341
  • Novartis$247
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$6,80499%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,893 in reported general payments places this provider in the 70th percentile of 105 neurology providers in Nebraska.

See all neurology providers in Nebraska

Medicare billing

Part B allowed, 2024
$146,604
Medicare patients
396
Services billed
7,396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate22$195,337
VumerityDiroximel Fumarate12$102,440
CopaxoneGlatiramer Acetate13$74,599
Aimovig AutoinjectorErenumab-Aooe70$65,195
UbrelvyUbrogepant47$60,783
NuplazidPimavanserin Tartrate12$56,633
GlatopaGlatiramer Acetate12$52,852
Nurtec OdtRimegepant Sulfate41$50,750
QuliptaAtogepant46$45,610
Emgality SyringeGalcanezumab-Gnlm33$22,528
Emgality PenGalcanezumab-Gnlm30$20,792
Tetrabenazine20$20,722
XcopriCenobamate13$14,367
Levetiracetam331$11,696
Carbidopa-LevodopaCarbidopa/Levodopa212$6,263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$112$195,33722 claims
AbbVieUbrelvy, Qulipta$915$106,39393 claims
BiogenVumerity$359$102,44012 claims
Teva Pharmaceuticals USA, Inc.Copaxone$133$74,59913 claims
Acadia Pharmaceuticals IncNuplazid$203$56,63312 claims
PfizerNurtec Odt$142$50,75041 claims
SK Life Science, Inc.Xcopri$145$14,36713 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$59$1,77311 claims
Upsher-smith Laboratories LLCTopiramate$84$1,650108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 105 neurology providers in Nebraska.

Other neurology in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →